Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jamey Weichert
University of Wisconsin Madison, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cellectar Biosciences
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
This outside activity has a nexus with the investigator's research activities because the outside activity arises from and relies upon the academic expertise that qualifies this individual to participate in this PHS funded research activity.The combination of the investigator's significant financial interest in the outside activity and the nexus between the investigator's research corresponds to the definition of a FCOI and so requires management.
A cancer-targeted phospholipid ether analog for molecular radiotherapy of pediatric solid tumors
Most children with relapsed or primary refractory solid tumors have a very poor prognosis. External beam radiotherapy plays a critical part in treatment of these tumors, but its role in the setting of metastatic disease is limited. This R21 application wil investigate the highly tumor selective phospholipid ether analog CLR1404 as scaffold for delivery of radioiodine isotopes for molecular radiotherapy and personalized dosimetry in pre- clinical rodent models of pediatric solid cancers. The project has a strong potential to increase the dismal survival rate of children with these particularly deadly tumors.
Filed on May 28, 2015.
Tell us what you know about Jamey Weichert's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jamey Weichert”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jamey Weichert | University of Wisconsin Madison | Conflict of Interest | Archeus Technologies | >$600,000 |
| Jamey Weichert | University of Wisconsin Madison | Conflict of Interest | Archeus Technologies | Value cannot be readily determined |
| Jamey Weichert | University of Wisconsin Madison | Conflict of Interest | Cellectar Biosciences | $150,000 - $199,999 |
| Jamey Weichert | University of Wisconsin Madison | Conflict of Interest | Archeus Technologies | $100,000 - $149,999 |
| Jamey Weichert | University of Wisconsin Madison | Conflict of Interest | Cellectar Biosciences | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.